SUBSCRIBE
SUBSCRIBE

Synexa Life Sciences

Synexa Life Sciences is a biomarker and bioanalytical lab CRO, specialising in the development, validation and delivery of a wide range of complex and custom-designed assays.

With a team of over 200 staff across three global laboratory locations; Manchester, Turku (Finland) and Cape Town, we provide innovative solutions to support our customers to achieve their clinical milestones.

Our main areas of expertise include biomarker identification and development, large and small molecule clinical bioanalysis, (soluble) biomarker analysis (utilising MSD, LC-MS/MS, ELISA, RIA, fluorescence and luminescence-based technologies), cell biology (including flow cytometry, ELISpot and Fluorospot) and genomic services to support clinical trials and translational studies.

We pride ourselves on our deep scientific expertise and ability to tackle complex problems, translating them into robust and reliable assays to support clinical trial sample analysis.

NEWS
Pfizer CEO Albert Bourla speaks at the Oval Office, standing in front of a lectern next to President Donald Trump, Mehmet Oz, Robert F Kennedy Jr
Drug pricing
Pfizer To Offer Drugs at a Discount in Agreement with US Government
Pfizer CEO Albert Bourla directly credited the threat of tariffs with leading to the deal, in which the company will offer drugs on a soon-to-be-launched website called TrumpRx.
September 30, 2025
 · 
2 min read
 · 
Dan Samorodnitsky
IN PARTNERSHIP WITH ELEMENT
Webinar: Resilience Through Reinvention: How Pharma is Navigating Uncertainty During Turbulent Times
In this discussion, our guests give their observations and recommendations on how companies can navigate within the United States market and beyond. Watch now.
September 30, 2025
 · 
1 min read
 · 
BioSpace Insights
Company downsizing, staff reduction and layoffs. Employee dismissal, firing and unemployment. Business concept.
Layoffs
Sutro Makes Deeper Cuts To Extend Runway Into 2027, Reach Key Data Readout
After parting with 50% of its employees earlier this year, Sutro Biopharma will lay another third of its staff in a restructuring effort geared toward reaching key inflection points.
September 30, 2025
 · 
1 min read
 · 
Dan Samorodnitsky
Achieve goal concept art collage. Rising arrow chart and halftone hand pointing to center of dartboard. Business goal, achieve targets, success. Trendy modern retro vector illustration
Obesity
Metsera’s Obesity Drug Shows ‘Very Encouraging’ Mid-Stage Efficacy, Supporting Pfizer’s $4.9B Bet
MET-097i’s mid-stage performance “bodes well” for Pfizer’s proposed buyout of Metsera, according to BMO Capital Markets, a deal centered heavily on the investigational GLP-1 drug.
September 30, 2025
 · 
2 min read
 · 
Tristan Manalac
Stagflation, economic slow down or recession while inflation high up, GDP growth decrease causing by unemployment concept, fearful businessman riding fall down economic graph with inflation high up.
Friedreich’s ataxia
Larimar’s Friedreich’s Ataxia Drug Troubled by Anaphylaxis Concerns; Shares Fall
Despite tolerability concerns, nomlabofusp’s overall efficacy represents a “large win” for Larimar, according to analysts at William Blair, who lauded the therapy’s functional benefits.
September 30, 2025
 · 
2 min read
 · 
Tristan Manalac
Rheumatoid arthritis (RA) commonly causes inflammation in the hands, leading to pain, swelling, and stiffness in the joints, particularly the small joints of the fingers and wrists. This inflammation results from the immune system attacking the body's own joint tissues, causing the synovium (lining of the joint) to become inflamed and release chemicals that damage nearby tissues.
Series A
Novo-Backed Crystalys Debuts With $205M to Tackle Gout
Already approved in Japan, China and other Asian countries, Crystalys’ dotinurad works to lower serum uric acid levels.
September 30, 2025
 · 
2 min read
 · 
Tristan Manalac
FDA CDER director George Tidmarsh speaking in an FDA video
Regulatory
FDA’s Tidmarsh Singles Out Aurinia’s Drug in LinkedIn Post About Surrogate Endpoints
Without naming Aurinia Pharmaceuticals, the CDER director in a now-deleted LinkedIn post claimed that for lupus nephritis, companies have not conducted post-approval studies “to demonstrate a benefit on hard clinical endpoints.”
September 30, 2025
 · 
2 min read
 · 
Tristan Manalac
Close-up of medical ampoule production line/iStock
Manufacturing
Drug Manufacturers See Long-Term Opportunity in Climbing AI Use
Companies are moving from using AI for distinct operations to applying the technology for control and optimization of the whole production process.
September 30, 2025
 · 
4 min read
 · 
Nick Paul Taylor
White house with pills and medicines, capsules
Opinion
How To Bring Generic Drug Manufacturing Back to the US
Reshoring generic pharmaceutical production is essential in today’s era of geopolitical instability and heightened awareness surrounding national health security. And it is possible—if done right.
September 30, 2025
 · 
5 min read
 · 
Vic Suarez
Load More
Visit website
Email Us
IN THE PRESS
Press Releases
Waters Sets a New Benchmark for Robustness and Sensitivity for High-Throughput Labs with the Xevo TQ Absolute XR Mass Spectrometer
June 2, 2025
 · 
4 min read
BioMidwest
Inotiv, Inc. Announces New Site Openings and Expansions Supporting Additional Capacity and Service Offerings
December 8, 2022
 · 
4 min read
Business
Parexel Announces Strategic Collaboration with Synexa Life Sciences and Drawbridge Health for COVID-19 Clinical Serology Testing Solution
November 2, 2020
 · 
4 min read
JOBS